These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38226605)

  • 1. Circulating biomarker analyses in a longitudinal cohort of patients with IPF.
    Ebert C; Walsh AM; Sereda L; Wilson CL; Schafer PH; Fischer A; Zhao L; Ramirez-Valle F; Gordon D; Schnapp LM
    Am J Physiol Lung Cell Mol Physiol; 2024 Mar; 326(3):L303-L312. PubMed ID: 38226605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis.
    Adegunsoye A; Alqalyoobi S; Linderholm A; Bowman WS; Lee CT; Pugashetti JV; Sarma N; Ma SF; Haczku A; Sperling A; Strek ME; Noth I; Oldham JM
    Chest; 2020 Oct; 158(4):1526-1534. PubMed ID: 32450241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
    Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
    Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATP-induced fibrogenic pathway in circulating cells obtained by idiopathic pulmonary fibrotic (IPF) patients is not blocked by nintedanib and pirfenidone.
    Colarusso C; Falanga A; Di Caprio S; Terlizzi M; D'Andria E; Antonio M; Maiolino P; Sorrentino R
    Biomed Pharmacother; 2024 Jul; 176():116896. PubMed ID: 38876049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
    Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
    BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials.
    Neighbors M; Cabanski CR; Ramalingam TR; Sheng XR; Tew GW; Gu C; Jia G; Peng K; Ray JM; Ley B; Wolters PJ; Collard HR; Arron JR
    Lancet Respir Med; 2018 Aug; 6(8):615-626. PubMed ID: 30072107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
    Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
    BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis.
    DePianto DJ; Chandriani S; Abbas AR; Jia G; N'Diaye EN; Caplazi P; Kauder SE; Biswas S; Karnik SK; Ha C; Modrusan Z; Matthay MA; Kukreja J; Collard HR; Egen JG; Wolters PJ; Arron JR
    Thorax; 2015 Jan; 70(1):48-56. PubMed ID: 25217476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
    Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
    Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-transcriptome-based candidate therapeutic discovery for idiopathic pulmonary fibrosis.
    Wang Y; Yella JK; Ghandikota S; Cherukuri TC; Ediga HH; Madala SK; Jegga AG
    Ther Adv Respir Dis; 2020; 14():1753466620971143. PubMed ID: 33167785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of nintedanib and pirfenidone on lung function and survival in patients with idiopathic pulmonary fibrosis in real-life setting.
    Santos G; Fabiano A; Mota PC; Rodrigues I; Carvalho D; Melo N; Novais-Bastos H; Alexandre AT; Moura CS; Guimarães S; Pereira JM; Carvalho A; Morais A
    Pulm Pharmacol Ther; 2023 Dec; 83():102261. PubMed ID: 37758002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort.
    Todd JL; Vinisko R; Liu Y; Neely ML; Overton R; Flaherty KR; Noth I; Newby LK; Lasky JA; Olman MA; Hesslinger C; Leonard TB; Palmer SM; Belperio JA;
    BMC Pulm Med; 2020 Mar; 20(1):64. PubMed ID: 32171287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan.
    Ikeda K; Chiba H; Nishikiori H; Azuma A; Kondoh Y; Ogura T; Taguchi Y; Ebina M; Sakaguchi H; Miyazawa S; Suga M; Sugiyama Y; Nukiwa T; Kudoh S; Takahashi H;
    Respir Res; 2020 Nov; 21(1):316. PubMed ID: 33256760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis.
    Lehtonen ST; Veijola A; Karvonen H; Lappi-Blanco E; Sormunen R; Korpela S; Zagai U; Sköld MC; Kaarteenaho R
    Respir Res; 2016 Feb; 17():14. PubMed ID: 26846335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYFRA 21.1 in bronchoalveolar lavage of idiopathic pulmonary fibrosis patients.
    Vercauteren IM; Verleden SE; McDonough JE; Vandermeulen E; Ruttens D; Lammertyn EJ; Bellon H; De Dycker E; Dooms C; Yserbyt J; Verleden GM; Vanaudenaerde BM; Wuyts WA
    Exp Lung Res; 2015; 41(8):459-65. PubMed ID: 26381718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idiopathic Pulmonary Fibrosis: Where do We Stand and How Far to Go?
    Singh V; Ulasov I; Gupta S; Singh A; Roy VK; Kharwar RK
    Discov Med; 2024 Jan; 36(180):22-47. PubMed ID: 38273744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma LTBP2 as a potential biomarker in differential diagnosis of connective tissue disease-associated interstitial lung disease and idiopathic pulmonary fibrosis: a pilot study.
    Zou M; Hu X; Song W; Gao H; Wu C; Zheng W; Cheng Z
    Clin Exp Med; 2023 Dec; 23(8):4809-4816. PubMed ID: 37864077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lung gene expression and single cell analyses reveal two subsets of idiopathic pulmonary fibrosis (IPF) patients associated with different pathogenic mechanisms.
    Karman J; Wang J; Bodea C; Cao S; Levesque MC
    PLoS One; 2021; 16(3):e0248889. PubMed ID: 33755690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYFRA 21-1 Predicts Progression in Idiopathic Pulmonary Fibrosis: A Prospective Longitudinal Analysis of the PROFILE Cohort.
    Molyneaux PL; Fahy WA; Byrne AJ; Braybrooke R; Saunders P; Toshner R; Albers G; Chua F; Renzoni EA; Wells AU; Karkera Y; Oballa E; Saini G; Nicholson AG; Jenkins RG; Maher TM
    Am J Respir Crit Care Med; 2022 Jun; 205(12):1440-1448. PubMed ID: 35363592
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.